Нибентан: препарат для фармакологической кардиоверсии при персистирующей фибрилляции предсердий.

Standard

Нибентан: препарат для фармакологической кардиоверсии при персистирующей фибрилляции предсердий. / Shubik, Yu V.; Medvedev, M. M.; Rivin, A. E.

In: КАРДИОЛОГИЯ , Vol. 45, No. 3, 01.12.2005, p. 19-23.

Research output: Contribution to journal › Article › peer-review

BibTeX

@article{ca1599b755294635bcd6eb2a36f0452c,

title = "Нибентан: препарат для фармакологической кардиоверсии при персистирующей фибрилляции предсердий.",

abstract = "Aim. To assess efficacy of a potassium channel blocker nibentan for pharmacological cardioversion of persistent atrial fibrillation. Method. Nibentan (1% solution) was infused intravenously after 3 weeks of warfarin pretreatment to 31 patients with duration of atrial fibrillation from 4 weeks to 15 months. Results. Sinus rhythm was restored in 24 patients. Mean dose of nibentan was 0.119±0.02 mg/kg. Proarrhythmic effects (paroxysmal or nonsustained polymorphic ventricular tachycardia) and substantial suppression of sinus rhythm automatism were registered in 3 and 3 patients, respectively. Conclusion. Nibentan is highly effective in persistent atrial fibrillation. It can be recommended for inhospital use in intensive care facilities.",

keywords = "Antiarrhythmic drugs, class III, Atrial fibrillation, persistent, Cardioversion, pharmacological, Nibentan",

author = "Shubik, {Yu V.} and Medvedev, {M. M.} and Rivin, {A. E.}",

year = "2005",

month = dec,

day = "1",

language = "русский",

volume = "45",

pages = "19--23",

journal = "КАРДИОЛОГИЯ ",

issn = "0022-9040",

publisher = "Медицина",

number = "3",

}

RIS

TY - JOUR

T1 - Нибентан: препарат для фармакологической кардиоверсии при персистирующей фибрилляции предсердий.

AU - Shubik, Yu V.

AU - Medvedev, M. M.

AU - Rivin, A. E.

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Aim. To assess efficacy of a potassium channel blocker nibentan for pharmacological cardioversion of persistent atrial fibrillation. Method. Nibentan (1% solution) was infused intravenously after 3 weeks of warfarin pretreatment to 31 patients with duration of atrial fibrillation from 4 weeks to 15 months. Results. Sinus rhythm was restored in 24 patients. Mean dose of nibentan was 0.119±0.02 mg/kg. Proarrhythmic effects (paroxysmal or nonsustained polymorphic ventricular tachycardia) and substantial suppression of sinus rhythm automatism were registered in 3 and 3 patients, respectively. Conclusion. Nibentan is highly effective in persistent atrial fibrillation. It can be recommended for inhospital use in intensive care facilities.

AB - Aim. To assess efficacy of a potassium channel blocker nibentan for pharmacological cardioversion of persistent atrial fibrillation. Method. Nibentan (1% solution) was infused intravenously after 3 weeks of warfarin pretreatment to 31 patients with duration of atrial fibrillation from 4 weeks to 15 months. Results. Sinus rhythm was restored in 24 patients. Mean dose of nibentan was 0.119±0.02 mg/kg. Proarrhythmic effects (paroxysmal or nonsustained polymorphic ventricular tachycardia) and substantial suppression of sinus rhythm automatism were registered in 3 and 3 patients, respectively. Conclusion. Nibentan is highly effective in persistent atrial fibrillation. It can be recommended for inhospital use in intensive care facilities.

KW - Antiarrhythmic drugs, class III

KW - Atrial fibrillation, persistent

KW - Cardioversion, pharmacological

KW - Nibentan

UR - http://www.scopus.com/inward/record.url?scp=33644960905&partnerID=8YFLogxK

M3 - статья

C2 - 15821703

VL - 45

SP - 19

EP - 23

JO - КАРДИОЛОГИЯ

JF - КАРДИОЛОГИЯ

SN - 0022-9040

IS - 3

ER -

ID: 5370421